Kazuhisa Yoshimura

Best Publications

• SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.

  Petra Mlcochova;Steven A Kemp;Steven A Kemp;Mahesh Shanker Dhar;Guido Papa

  1313
  Citations

• Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

  Unknown

  738
  Citations

• Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

  Akatsuki Saito;Takashi Irie;Rigel Suzuki;Tadashi Maemura;Tadashi Maemura

  651
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

  Unknown

  522
  Citations

• Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

  Unknown

  466
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5

  Unknown

  435
  Citations

• Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

  Unknown

  287
  Citations

• Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis

  Bruce C. Trapnell;Chin-Shyan Chu;Paavo K. Paakko;Tyrone C. Banks

  277
  Citations

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Kazuhisa Yoshimura;Ryohei Kato;Mark F. Kavlick;Aline Nguyen

  209
  Citations

• Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors

  Hiroyuki Gatanaga;Yasuhiro Suzuki;Hsinyi Tsang;Kazuhisa Yoshimura;Kazuhisa Yoshimura

  205
  Citations

• Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5

  Kenji Maeda;Kazuhisa Yoshimura;Shiro Shibayama;Hiromu Habashita

  197
  Citations

• Virological characteristics of SARS-CoV-2 BA.2 variant

  Unknown

  187
  Citations

• JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1

  Kazuhisa Yoshimura;Ryohei Kato;Keisuke Yusa;Mark F. Kavlick

  159
  Citations

• Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

  Unknown

  155
  Citations

• Current status of HIV/AIDS in the ART era.

  Unknown

  154
  Citations

• Recurrent HIV‐1 Integration at the<i>BACH2</i>Locus in Resting CD4⁺T Cell Populations during Effective Highly Active Antiretroviral Therapy

  Unknown

  130
  Citations

• Syntheses of 4‘-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity

  Hiroshi Ohrui;Satoru Kohgo;Kenji Kitano;Shinji Sakata

  119
  Citations

• Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

  Kazuhisa Yoshimura;Shigeyoshi Harada;Junji Shibata;Makiko Hatada

  109
  Citations

• Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity

  J Falloon;S Piscitelli;S Vogel;B Sadler

  109
  Citations

• SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag

  Akihide Ryo;Naomi Tsurutani;Kenji Ohba;Ryuichiro Kimura

  104
  Citations